DOCSLIB.ORG

WISTAR SCIENCE in the WORLD ANNUAL REPORT 20 07 112798W1 5/30/08 1:17 AM Page 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WISTAR SCIENCE in the WORLD ANNUAL REPORT 20 07 112798W1 5/30/08 1:17 AM Page 2 112798W1 5/30/08 1:17 AM Page 1 MAKING AN IMPACT WISTAR SCIENCE IN THE WORLD ANNUAL REPORT ANNUAL 20 07 112798W1 5/30/08 1:17 AM Page 2 Products developed from Wistar science are protecting the lives of children and adults in the United States and across the globe. 112798W1 5/30/08 1:17 AM Page 3 Every lifesaving medical advance – every new medicine, vaccine, or diagnostic test – starts with a question. How can this disease be treated? How can we protect against infection by this virus? How can we detect this illness sooner? Questions like these drive the work of the scientists at The Wistar Institute. But finding answers is just the first step in helping people to live longer, healthier lives. This is the story of how Wistar’s scientific breakthroughs have touched lives all over the world – and the exciting research that offers new hope for the future. 112798W1 5/30/08 1:17 AM Page 4 FROM THE PRESIDENT hances are that Wistar science has touched your life. The “MMR” shot you received as a toddler included Wistar’s vaccine against rubella, along Cwith vaccines against measles and mumps. Thanks in part to Wistar, people living in the United States and other industrialized nations have little to fear from rabies. And babies born today in the United States and many other countries will receive a rotavirus vaccine co-developed by Wistar researchers that will protect them from a potentially deadly gastrointestinal illness. Wistar’s focus on cancer research has contributed to new and better cancer drugs, as well as a diagnostic test for breast cancer patients. Therapies based on Wistar’s work are showing promise in the treatment of other serious diseases as well. The impact of Wistar’s research has been felt worldwide – in lives saved, suffering avoided, and knowledge gained. Wistar is dedicated to basic research – investigation driven by a researcher’s interest in a fundamental scientific question. But Wistar also works to ensure that its scientific breakthroughs benefit people in need, from a child facing disease in a developing country to a cancer patient desperate for better treatments. That’s why the Institute has been partnering for decades with biotechnology and pharmaceutical companies that can turn its scientific advances into products such as vaccines, medicines, and diagnostic tests. Wistar’s efforts to commercialize its inventions produce other benefits as well. Through my work with the CEO Council for Growth, an affiliate of the Greater Philadelphia Chamber of Commerce, I have come to appreciate the critical role of technology transfer – the process of moving a discovery from a laboratory into commercial development – in growing the economy. In fact, a recent report, commissioned by the council, identified technology transfer as the key to Philadelphia realizing its potential as one of the nation’s great centers of economic development. Commercialization activities can generate start-up companies, attract venture capital investment, and stimulate job growth. Even more importantly, Wistar’s research contributes to another vital resource: knowledge. Our scientists distribute their findings through conferences and publications, contributing immeasurably to the work of other researchers in academic and industry labs. None of this progress would be possible without the support of the many generous Wistar friends and donors who recognize the importance of the Institute’s mission and embrace it as their own. In these pages, you will learn how Wistar’s research has improved public health. You will read about the dedicated Wistar scientists who are making inroads in the battle against deadly diseases. You will meet the people who are making a difference in the lives of others, both inside the lab and out. The vision, dedication, and determination of these individuals will continue to lead us to new discoveries – and new hope. Russel E. Kaufman, M.D. President and CEO 112798W1 5/30/08 1:17 AM Page 5 TABLE OF CONTENTS Journey of a Discovery: Working to Benefit Public Health . 4 In the Making: An Early Warning of Lung Cancer . 6 Looking Back: A Legacy of Impact . 8 On the Horizon: Targeting a Killer Enzyme . 10 The Year in Review: Scientific Highlights . .12 The Year in Review: The Institute at a Glance . .15 Looking Ahead: Finding New Hope Against Cancer . .16 Letter from the Chair . .19 Cumulative Giving . 20 Leroy Kean: Investing in Results . 21 Annual Giving . 23 Rich Beston: A Survivor’s Story . 25 Scientific Staff . 31 Administrative Staff . 32 Volunteer Leadership . inside back cover 112798W1 5/30/08 1:17 AM Page 6 JOURNEY OF A DISCOVERY WORKING TO BENEFIT PUBLIC HEALTH WISTAR WORKS TO MAKE SURE ITS SCIENTIFIC ADVANCES BENEFIT THOSE IN NEED—AND THAT TAKES FUNDING, PERSISTENCE, AND COLLABORATION. istar’s mission is to improve global public health through its scientific achievements. But a discovery that takes place in a Wistar laboratory is just the first step in that process. WLong before many peer organizations, Wistar began to seek out industry partners who could develop the Institute’s research into medicines, vaccines, and diagnostic tests that could benefit the public. “We want our scientific advances to improve the health of people worldwide, and we have a proud track record of making that happen,” says Russel E. Kaufman, M.D., Wistar’s president and CEO. “We make it a priority to get our inventions into the commercial sector so they can benefit the people who really need them.” From the lab to the clinic The path from the laboratory to your doctor’s office or medicine cabinet begins with an idea that a scientist wants to pursue. At this stage, funding is crucial.Without support from the government, foundations, and private donors, even the most promising project cannot get off the ground. Once scientists receive funding, begin their experiments, and gather results, the process of transforming research advances into new products can still take many years. “When you’re talking about early-stage research becoming a product in the pharmaceutical or biotechnology area, there is a huge lag,” says Meryle J. Melnicoff, Ph.D., director of business development at Wistar. “That’s one of the reasons we need to support early-stage research. It takes a lot of years, a lot of hard work, and a lot of money to bring these things to the market.” Take the rotavirus vaccine co-developed at Wistar. Research on the project began in the 1980s, but the vaccine wasn’t approved for use until 2006. (See the timeline on pullout pages at right.) That “lag” occurred in part because of the need to conduct extensive safety and efficacy studies on the vaccine. The journey of a discovery is also a story of collaboration. After Wistar researchers make discoveries that have the potential to help people, the Institute partners with organizations such as phar- maceutical and biotechnology companies that have the resources and expertise to further develop the technology and bring it to market. “Our commercial partners play an essential role in delivering the benefits of our research to the public,” Melnicoff says. “We work actively to build and sustain these relationships so that our research has the greatest possible impact.” 4 ANNUAL REPORT 2007 112798W1 5/30/08 1:33 AM Page 7 FAST FACTS • Funding from the government, foundations, and private donors helps research projects get off the ground. • Wistar was a pioneer in working with industry to deliver the benefits of research to the public. and • Developing a research discovery into a new drug, vaccine, or diagnostic test can take 10 to ex-smokers 20 years or longer. • Collaborations between Wistar in the and industry help to drive regional economic growth by creating jobs. United States.” < < LIFT PAGE FOR TIMELINE. 112798W1 5/30/08 1:17 AM Page 9 ROTAVIRUS BIRTH OF A VACCINE A STORY OF PATIENCE AND PARTNERSHIP DEVELOPING A SCIENTIFIC ADVANCE INTO A NEW DRUG, VACCINE, OR DIAGNOSTIC TEST CAN TAKE 10 TO 20 YEARS OR LONGER. THAT TIME IS SPENT ON RESEARCH, COLLABORATION, AND TESTING. THE ROTAVIRUS VACCINE CO-DEVELOPED AT WISTAR WAS NO EXCEPTION. Wistar scientists Stanley A. Wistar files the first patent Wistar and CHOP partner Plotkin, M.D., and H. Fred application on a promising with a major pharmaceutical Clark, D.V.M., Ph.D., begin early vaccine prototype. company to continue clinical research on a rotavirus development of the vaccine. vaccine. They are joined by Paul A. Offit, M.D., of Children’s Hospital of Philadelphia, launching a Wistar/CHOP collaboration that continues throughout the research project. H. Fred Clark, D.V.M.,Ph.D., right, Stanley A. Plotkin, M.D., Wistar adjunct professor, Wistar professor emeritus research professor of pediatrics at Children’s Hospital of Philadelphia Paul A. Offit, M.D., left, Wistar adjunct professor, chief of infectious diseases at Children’s Hospital of Philadelphia . 1980 1985 1991 . 112798W1 5/30/08 1:17 AM Page 10 ABOUT ROTAVIRUS Rotavirus causes severe dehydration illness in infants and young children. It infects virtually all American children by the time they reach age 5, causing some 250,000 emer- gency room visits and 70,000 hospitalizations annually. In the developing world, where medical facilities are limited, the infection kills 600,000 infants and children each year. Major clinical trials are After the vaccine is proven The rotavirus vaccine is In addition to being widely launched to assess the safe and effective, the phar- approved for use by the used in the United States, vaccine’s safety and efficacy. maceutical company FDA and becomes part of the rotavirus vaccine has In the largest vaccine trial applies to the Food and the recommended vaccine been launched in 47 other ever performed by a phar- Drug Administration for schedule for all U.S.
Load more

Recommended publications
  • Of Aging: Wistar Researchers Shed New Light on Getting Old
    ocus F Summer 2008 The Science of Aging: Wistar researchers shed new light on getting old Wistar Launches High-Tech Research Center The Federal Funding Crunch: What Does It Mean for Wistar? FROM THE PRESIDENT Wistar: Research at the Frontier he Wistar Institute has a pioneering tradition. TCaspar Wistar, for whom the Institute is named, was a forward-thinking 18th-century physician who wrote the first American anatomy textbook and was an early proponent of vaccination. His great-nephew, Insti- tute founder Isaac J. Wistar, was a pioneer in his own right who trekked west by wagon train to spend winters as a trapper in the wilds of California. Isaac Wistar founded The Wistar Institute in 1892 with the stated intention of creating a center for “new and original research” in the biological and medical sci- Peter Olson ences. In the ensuing century, Wistar lived up to that charge, and it continues to do so today. massive amounts of data and pinpoint disease-causing Wistar’s first scientific advisory board, convened in genes and proteins. The center supports work like that of 1905, declared research as the Institute’s principal objec- David W. Speicher, Ph.D., who is developing blood tests tive and specified three areas of focus: comparative for the early detection of the deadliest cancers. anatomy, embryology, and neurology—fields that repre- Likewise, the Institute’s new chemical screening facil- sented the leading edge of science and medicine at the ity, set to launch this fall, will allow investigators to turn of the century. screen vast numbers of compounds and identify those The Institute’s research focus has evolved over the years.
    [Show full text]
  • 2016 Calendar of Events
    CALENDAR OF EVENTS OF EVENTS CALENDAR FEBRUARY 2 — MARCH 30, 2016 2 — MARCH 30, FEBRUARY EIGHT INSPIRED WEEKS OF DISCUSSIONS, PERFORMANCES, AND FILMS 2016 FEATURED TITLES FEATURED 2016 WELCOME 2016 FEATURED TITLES pg 2 WELCOME FROM THE CHAIR pg 3 YOUTH COMPANION BOOKS pg 4 ADDITIONAL READING SUGGESTIONS pg 5 DISCUSSION GROUPS AND QUESTIONS pg 6-7 FILM SCREENINGS pg 8-9 GENERAL EVENTS pg 10 EVENTS FOR CHILDREN, TEENS, AND FAMILIES pg 21 COMMUNITY PARTNERS pg 27 SPONSORS AND ACKNOWLEDGEMENTS pg 30 The centerpiece of 2016 One Book, One Philadelphia is author Charles Frazier’s historical novel Cold Mountain. Set at the end of the Civil War, Cold Mountain tells the heartrending story of Inman, a wounded Confederate soldier who walks away from the horrors of war to return home to his beloved, Ada. Cold Mountain BY CHARLES FRAZIER His perilous journey through the war-ravaged landscape of North Carolina Cold Mountain made publishing history when it topped the interweaves with Ada’s struggles to maintain her father’s farm as she awaits New York Times bestseller list for 61 weeks and sold 3 million Inman’s return. A compelling love story beats at the heart of Cold Mountain, copies. A richly detailed American epic, it is the story of a Civil propelling the action and keeping readers anxiously turning pages. War soldier journeying through a divided country to return Critics have praised Cold Mountain for its lyrical language, its reverential to the woman he loves, while she struggles to maintain her descriptions of the Southern landscape, and its powerful storytelling that dramatizes father’s farm and make sense of a new and troubling world.
    [Show full text]
  • Stanley A. Plotkin, MD
    55936.qxp 3/10/09 4:27 PM Page 4 Stanley A. Plotkin, MD Recipient of the 2009 Maxwell Finland Award for Scientific Achievement hysician, scientist, scholar—Stanley Plotkin Dr. Plotkin was born in New York City. His father was a has successfully juggled all three roles during commercial telegrapher. His mother, who occasionally his decades of service. filled in as an accountant, mostly stayed home with Stanley PFrom his first job following graduation from and his younger sister, Brenda. At age 15, Stanley, a student medical school as an intern at Cleveland Met- at the Bronx High School of Science, discovered what he ropolitan General Hospital to his present role as consultant wanted to do with his life. After reading the novel Arrow - to the vaccine manufacturer sanofi pasteur, Dr. Plotkin has smith by Sinclair Lewis and the nonfictional work Microbe explored the world of infectious diseases and Hunters by Paul de Kruif—two books about sci- has been actively involved in developing some entists battling diseases—Stanley set his sights of the most potent vaccines against those dis- on becoming a physician and a research scien- eases. tist. “Dr. Plotkin has been a tireless advocate for Dr. Plotkin graduated from New York Uni- the protection of humans, and children in par- versity in 1952 and obtained a medical degree ticular, from preventable infectious diseases. at Downstate Medical Center in Brooklyn. He His lifetime of work on vaccines has led to pro- was a resident in pediatrics at the Children’s found reductions in both morbidity and mortality not only Hospital of Philadelphia and at the Hospital for Sick Chil- in the United States, but throughout the world,” says Vi- dren in London.
    [Show full text]
  • Novel Approach for Vaccine Development Leads to Discovery Of
    For Immediate Release: Contact: Nov. 14, 2014 Darien Sutton [email protected] 215 898 3988 Dr. Stanley A. Plotkin to Receive the Hamdan Award for Medical Research Excellence in the Field of Vaccines PHILADELPHIA–(Nov. 14, 2014)–Renowned vaccine researcher Stanley A. Plotkin, M.D., emeritus professor at The Wistar Institute, will receive the Hamdan Award for Medical Research Excellence in the field of Vaccines on Dec. 16 at the Dubai International Conference for Medical Sciences. Sheikh Hamdan bin Rashid Al Maktoum, deputy ruler of Dubai and Finance and Industry minister of the United Arab Emirates, will present the award to Plotkin, who will speak about the future of vaccine development and conduct a workshop on vaccines. Established in 1999 to honor the work of researchers across the globe, the Hamdan Award is part of an Emirati initiative that calls upon health institutes worldwide to promote plans for specific research and scientific study to improve lives. Plotkin has spent a lifetime developing and improving vaccines to fight a host of preventable diseases and save countless lives in the U.S. and around the world. The majority of his more than 50-year career was spent as a professor of virology at Wistar, from 1960-1991, where his groundbreaking research led to the creation of the rubella vaccine against German measles–the lone standard used worldwide to this day–as well as vaccines used to prevent cytomegalovirus, polio, and varicella. His active study spanned decades, from the 1960s when he worked on a rabies vaccine, to 2006, when he collaborated on a rotavirus vaccine, which is now part of the standard schedule of pediatric immunizations recommended by the Centers for Disease Control.
    [Show full text]
  • Plotkin SHORT CV
    SHORT CV Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught, where for seven years he was Medical and Scientific Director, based at Marnes-la-Coquette, outside Paris. The same company is now named Sanofi Pasteur. He is now consultant to vaccine manufacturers, biotechnology companies and non-profit research organizations as principal of Vaxconsult, LLC. Dr. Plotkin attended New York University, where he received a B.A. degree, and then the State University of New York Medical School in Brooklyn, where he received an M.D. degree in 1956. His subsequent career included internship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Children’s Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the US Public Health Service. He has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. Dr. Plotkin received the Bruce Medal in Preventive Medicine of the American College of Physicians, the Distinguished Physician Award of the Pediatric Infectious Diseases Society, the Clinical Virology Award of the Pan American Society for Clinical Virology, the Richard Day Master Teacher in Pediatrics Award of the Alumni Association of New York Downstate Medical College, and the Marshall Award of the European Society for Pediatric Infectious Diseases.
    [Show full text]
  • University Place Associates and the Wistar Institute Collaborate to Create New Research and Discovery Hub in Philadelphia's Un
    [EMBARGOED-- NFR UNTIL 6/3/19 4PM] UPA Contact: Rick Gillespie | [email protected] | 215-870-7000 Wistar Contact: Darien Sutton | [email protected] | 215-898-3988 University Place Associates and The Wistar Institute Collaborate to Create New Research and Discovery Hub in Philadelphia’s University City District Allows for establishment of collaborations among Wistar and academic research and biotechnology start-up communities in the region. PHILADELPHIA—(June 3, 2019)— University Place Associates (UPA) and The Wistar Institute have announced a strategic collaboration to curate a 240,000 square foot buildinG to be built by UPA dedicated to supporting the life sciences industry with state-of-the-art laboratory/office space in the heart of Philadelphia’s University City District. By providinG much-needed lab space and shared resource capacity to the Philadelphia reGion, this facility, to be located at 4101 Market Street, will deliver the critical infrastructure and support network needed to advance biomedical research. “There is so much to say about The Wistar Institute, its history, its ethos and its mission. We are humbled and excited to be working with this very special giant of life-saving scientific research,” commented Scott Mazo, founder and CEO of University Place Associates. “To have Wistar championinG the Philadelphia life sciences ecosystem at 3.0 University Place is terrific news for the city, the state, and the region.” “Early staGe discovery science requires both patience and urgency,” stated Dario C. Altieri, M.D., president and CEO at The Wistar Institute and director of its NCI-designated Cancer Center. “We now have an opportunity to build on the collaborations that are essential to changing the future of healthcare.
    [Show full text]
  • Dr. Joseph Leidy's Petrified Lady
    DR. JOSEPH LEIDY’S PETRIFIED LADY RUMMAGING IN THE MÜTTER MUSEUM, OF THE COLLEGE OF PHYSICIANS OF PHILADELPHIA By Joseph Mc Farl and , m .d . PHILADELPHIA MONGA our numerous and re- century—even in a closed case—and /vk markable possessions and a which it is impossible to remove be- /yk leading exhibit of our Miit- cause of the adhesive and crumbling ™ ■ ter Museum is an adipocere nature of the surface to which it is body commonly spoken of as “The attached. All that remains is a mass of Petrified Lady.” dirty, wrinkled, cracked and crumbling Just inside the door of the innermost waxy substance shaped in conformity to room of the lower floor, she lies in a a human figure. coffin-like case as though laid out for Few anatomical landmarks remain, what the morticians now speak of as but the breasts, once prominent, are, “viewing,” and although there is per- as in old age, now flattened against the fect quiet and dim lighting, there are chest wall. They, and the long thin no surrounding clusters of flowers to hair tied with a ribbon, are all that give off their funereal sweetness, no remain to determine the sex. friends and relatives to whisper in the The features are not easily made out, background, and no undertakers in but the open mouth is unmistakable solemn black silently flitting to and fro. and it is without a single tooth. No, it is not a funeral but an exhibi- Evidently our lady had a plump fig- tion, for her body, buried long ago ure and full breasts, but was old, and became changed to adipocere, and thus probably ugly, with a nut-cracker pro- has become an object of rare scientific file at the time of her death.
    [Show full text]
  • 750 Author Page MH SA.Indd
    AUTHORS Vol 459 | Issue no. 7248 | 11 June 2009 approach for work- Abstractions MAKING THE PAPER ing out how to build LAST AUTHOR a molecule. The In 1999, researchers Phil Baran process normally reported that increasing starts with a single production of the Sir2 Natural clues offer fresh route target molecule and protein in the yeast to chemical synthesis. works backwards, Saccharomyces cerevisiae breaking apart stra- extends the organism’s Phil Baran still remembers the date that he ven- tegic bonds to make lifespan. This and other tured into new territory. On 12 January 2007, simpler and simpler findings spurred a flurry of activity and the an editor at Nature Chemical Biology contacted molecules, to help identification of similar longevity proteins, him to ask whether he might write a review outline possible syn- dubbed sirtuins, in other organisms. But how sirtuins promote long life remains article on terpenes — a large class of naturally thesis strategies. unclear. Shelley Berger of the Wistar Institute occurring molecules that have applications in But terpene synthesis is complicated by the in Philadelphia, Pennsylvania, and her everything from perfumes to pesticides. Until fact that highly oxygenated molecules have colleagues have now uncovered a clue (see then, Baran, an organic chemist at the Scripps functional groups that can easily react with one page 802). As yeast cells age, Sir2, an enzyme Research Institute in La Jolla, California, had another or prevent key reactions from proceed- known as a deacetylase, becomes less worked only on nitrogen-containing com- ing. So chemists often have to remove a recently abundant and so less effective at removing pounds called alkaloids.
    [Show full text]
  • Protein 4.1B Expression Is Induced in Mammary Epithelial Cells During Pregnancy and Regulates Their Proliferation
    Oncogene (2005) 24, 6502–6515 & 2005 Nature Publishing Group All rights reserved 0950-9232/05 $30.00 www.nature.com/onc Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation Robin Kuns1,2, Joseph L Kissil3, Irene F Newsham4, Tyler Jacks5, David H Gutmann6 and Larry S Sherman*,1 1Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Ave., Beaverton, OR 97006, USA; 2Department of Cell Biology, Neurobiology & Anatomy, University of Cincinnati School of Medicine, Cincinnati, OH 45267, USA; 3Molecular and Cellular Oncogenomics Program, The Wistar Institute, Philadelphia, PA 19104, USA; 4Department of Neurosurgery, David and Doreen Hermelin Laboratory of Molecular Oncogenetics, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI 48202, USA; 5Department of Biology and Center for Cancer Research, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; 6Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA 4.1B is a member of the protein 4.1 superfamily of erythrocytes (Tyler et al., 1979). This superfamily proteins that link transmembrane proteins to the actin consists of five subgroups, including the 4.1 proteins cytoskeleton. The 4.1B gene localizes to chromosome (4.1R, 4.1N, 4.1G, 4.1O, and 4.1B) and the ERM 18p11.3, which undergoes loss of heterozygosity in proteins (ezrin, radixin, moesin, and merlin). All 4.1 mammary tumors. Here, we examine the expression of family members are characterized by the presence of a 4.1B in murine mammary epithelium and find that 4.1B is conserved N-terminal membrane-association FERM dramatically upregulated in mammary epithelial cells (Fourpoint-one, Ezrin, Radixin, Moesin) domain during pregnancy when there is extensive cell prolifera- (Chishti et al., 1998).
    [Show full text]
  • Stanley Alan Plotkin (1932– ) [1]
    Published on The Embryo Project Encyclopedia (https://embryo.asu.edu) Stanley Alan Plotkin (1932– ) [1] By: Ross, Christian H. Stanley Alan Plotkin developed vaccines in the United States during the mid to late twentieth century. Plotkin began his research career at the Wistar Institute in Philadelphia, Pennsylvania, where he studied the rubella virus. In pregnant women, the rubella virus caused congenital rubella syndrome in the fetus [2], which led to various malformations and birth defects [3]. Using WI-38 cells, a line of cells that originated from tissues of aborted fetuses, Plotkin successfully created RA27/3, a weakened strain of the rubella virus, which he then used to develop a rubella vaccine. Plotkin's rubella vaccine has prevented birth defects [3] due to congenital rubella in developing fetuses and newborns. Plotkin was born 12 May 1932 in New York City, New York, to parents Lee and Joseph Plotkin, who had immigrated to the United States from England. Plotkin's father worked as a commercial telegrapher while his mother cared for Plotkin and his younger sister, Brenda. As an adolescent, Plotkin attended the Bronx High School of Science in New York City, New York. When Plotkin was fifteen, he read two books, Arrowsmith, a novel by Sinclair Lewis, and Microbe Hunters, a non-fiction science drama by Paul de Kruif. Both books told stories of scientists striving to discover the causes of diseases and to create vaccines against them. Plotkin later credited those books as his inspiration for studying science and medicine. After graduating from the Bronx High School of Science in 1948, Plotkin enrolled at New York University in New York City.
    [Show full text]
  • LONG-TERM MEMBERS 25+ Years of Membership
    LONG-TERM MEMBERS 25+ Years of Membership Stuart A. Aaronson, MD Stephen P. Ackland, MBBS Carol Aghajanian, MD Steven A. Akman, MD Icahn School of Medicine at Mount Sinai University of Newcastle Memorial Sloan Kettering Cancer Center Roper St. Francis Healthcare United States Australia United States United States Active Member Active Member Active Member Active Member 38 Years of Membership 33 Years of Membership 27 Years of Membership 35 Years of Membership Cory Abate-Shen, PhD Edward M. Acton, PhD Irina U. Agoulnik, PhD Emmanuel T. Akporiaye, PhD Columbia University Irving Medical United States Florida International University Verana Therapeutics Center Emeritus Member United States United States United States 42 Years of Membership Active Member Emeritus Member Active Member 25 Years of Membership 31 Years of Membership 26 Years of Membership David J. Adams, PhD Duke University Medical Center Imran Ahmad, PhD Ala-Eddin Al Moustafa, PhD James L. Abbruzzese, MD United States Northwestern Medicine McGill University Duke University Emeritus Member United States Canada United States 32 Years of Membership Active Member Active Member Active Member 25 Years of Membership 26 Years of Membership 32 Years of Membership Gregory P. Adams, PhD Elucida Oncology Nihal Ahmad, PhD Abdul Al Saadi, PhD Ehtesham A. Abdi, MBBS United States Univ. of Wisconsin Madison Sch. of Med. William Beaumont Hospital The Tweed Hospital Active Member & Public Health United States Australia 29 Years of Membership United States Emeritus Member Emeritus Member Active Member 52 Years of Membership 33 Years of Membership Lucile L. Adams-Campbell, PhD 25 Years of Membership Georgetown Lombardi Comprehensive Suresh K.
    [Show full text]
  • 2019 Compass Conference
    The Association of Fundraising Professionals (AFP) represents nearly 31,000 members in more than 200 chapters throughout the 2019 Compass world, working to advance philanthropy through advocacy, research, education, and certification Conference programs. Founded in 1960 as the National Society of Fund Raisers, AFP fosters development and growth Navigating Philanthropy of fundraising professionals and promotes high ethical standards in the fundraising profession. One of the top 10 in Challenging Times largest AFP Chapters, the Greater Philadelphia Chapter was established in 1968 and has over 500 members. In addition to May 15, 2019 members, AFP-GPC has over 2,000 fundraising professionals who Temple University – receive information and event alerts via email. Whether you are new to the fundraising profession or a seasoned professional, a volunteer Main Campus involved in the philanthropic process or want to learn more about getting involved in philathrophy or development, AFP-GPC is your go-to resource for all things relating to fundraising in the Philadelphia area. www.afpgpc.org/compass_conference • [email protected] • 267.665.2700 WHY Attend AFP-GPC’s 3rd Annual Compass Conference will incorporate the theme Navigating Philanthropy in Challenging Times. You will learn strategies and walk away with tools and actionable tasks to equip your team, board, donors, and volunteers with the most up to date fundraising practices. You will also establish or re-energize your professional support system with friends, colleagues, and AFP members while choosing from 16 different sessions led by leaders in the fundraising profession. WHY Sponsor Compass Conference sponsorship will connect you with the Philadelphia’s regions most forward- thinking fundraising professionals who are responsible for recommending, selecting, and/or buying products and services.
    [Show full text]